Will imrx surge today

Immuneering's stock is likely to experience significant volatility today, September 20, 2024, due to several key factors:

1. Positive Clinical Trial Results: Immuneering has announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer as part of its ongoing Phase 2a clinical trial. This news has already caused a substantial spike in the stock price in the previous trading session, with shares surging by 47.55% to $2.11 in pre-market trading.
2. Upcoming Earnings Report: Immuneering is scheduled to release its Q2 2024 earnings report on August 6, 2024. While the earnings release has already passed, the market may still react to the results, especially if they exceed analysts' expectations, as indicated by the company's recent history of topping consensus estimates.
3. Analyst Ratings and Price Targets: Chardan Capital has raised its FY2024 earnings per share estimates for Immuneering, reflecting optimism about the company's financial performance. Additionally, Needham & Company LLC has reissued a "buy" rating and set a price target of $15.00, which is significantly higher than the current trading price.
4. Short-term Trend Forecast: The short-term trend forecast for Immuneering is not available, which makes it difficult to predict the stock's immediate movement.
5. Historical Performance: Immuneering has experienced substantial interval percentage changes, with a 69.23% change in the past week and a 126.17% change in the past month. This indicates a high level of market volatility and suggests that the stock's recent momentum could continue.
6. Market Sentiment: The overall market sentiment towards Immuneering is positive, with a consensus rating of "Moderate Buy" and a consensus price target of $12.60. This suggests that analysts believe the stock has potential for further appreciation.

In conclusion, while there is no specific forecast for today's trading, the combination of positive clinical trial results, upcoming earnings report, and favorable analyst ratings suggest that Immuneering's stock could experience a positive surge today. However, the lack of a short-term trend forecast and the historical volatility of the stock indicate that the actual performance could vary significantly.